Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth

Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth


Sales of BioThrax were down 26% year over year, but that was due to timing of delivery to the Strategic National Stockpile and was made up for entirely, and then some, by sales of its botulism antitoxin BAT, which were pushed from the fourth quarter into this one. Revenue from contract manufacturing increased 132% year over year.



from Biotech News